Progress over the past 30 years has revealed many strengths of the rainbow trout as an alternative model for environmental carcinogenesis research. These include low rearing costs, an early life-stage ultrasensitive bioassay, sensitivity to many classes of carcinogen, a well-described tumor pathology, responsiveness to tumor promoters and inhibitors, and a mechanistically informative nonmammalian comparative status. Low-cost husbandry, for example, has permitted statistically challenging tumor study designs with up to 10,000 trout to investigate the quantitative interrelationships among carcinogen dose, anticarcinogen dose, DNA adduct formation, and final tumor outcome. The basic elements of the trout carcinogen bioassay include multiple exposure routes, carcinogen response, husbandry requirements, and pathology. The principal known neoplasms occur in liver (mixed hepatocellular/cholangiocellular adenoma and carcinoma, hepatocellular carcinoma), kidney (nephroblastoma), swim bladder (adenopapilloma), and stomach (adenopapilloma). Trout possess a complex but incompletely characterized array of cytochromes P450, transferases, and other enzymic systems for phase and phase 11 procarcinogen metabolism. In general, trout exhibit only limited capacity for DNA repair, especially for removal of bulky DNA adducts. This factor, together with a high capacity for P450 bioactivation and negligible glutathione transferase-mediated detoxication of the epoxide, accounts for the exceptional sensitivity of trout to aflatoxin B1 carcinogenesis. At the gene level, all trout tumors except nephroblastoma exhibit variable and often high incidences of oncogenic Ki-ras gene mutations. Mutations in the trout p53 tumor suppressor gene have yet to be described. There are many aspects of the trout model, especially the lack of complete organ homology, that limit its application as a surrogate for human cancer research. Within these limitations, however, it is apparent that trout and other fish models can serve as highly useful adjuncts to conventional rodent models in the study of environmental carcinogenesis and its modulation. For some problems, fish models can provide wholly unique approaches.
Introduction
Fish have gained increasing attention over the past three decades as valuable models for environmental carcinogenesis research. Various fish species have been investigated as nonmammalian vertebrate models for carcinogen testing, as surrogates for understanding mechanisms of human cancer and its prevention, as feral species indicators of ecologic contamination, as indicators of potential human exposure to carcinogens in the water column or aquatic food chain, and for application as in situ field monitors of integrated carcinogenic hazard in groundwaters near toxic waste sites. Interest in the use of small aquarium fish species for cancer research arose from the pioneering work of Stanton (1) , who in 1965 demonstrated the hepatocarcinogenicity of N-nitrosodiethylamine (DEN) to the zebra danio. Table 1 presents a partial list of species used and carcinogens examined since that time. Exposures in these studies have included continuous or acute water bath treatment, dietary intake, or direct injection of embryos or later life stages. Additional species and carcinogens have been explored (23) (24) (25) , and comprehensive testing of 30 National Toxicology Program carcinogens in one species, the medaka, is in progress at the Duluth laboratory of the U.S. Environmental Protection Agency (R Johnson, personal communication).
Through work with various aquarium fish species, many attributes have been identified: their low cost, portability, and ease of laboratory culture; their potential for in situ field monitoring; and their potential for lifetime bioassay, short reproductive cycle, and ease of genetic studies. However, while aquarium fish models have distinct appeal, knowledge of mechanisms of carcinogenesis (e.g., procarcinogen metabolism, DNA adduction and repair, targeted oncogenes) and its modulation (inhibition, promotion-progression) by environmental and dietary factors is at present more advanced in the rainbow trout (Oncorhynchus mykiss).
Attention was drawn to this species in the early 1960s when epizootics of liver cancer in Pacific Northwest trout hatcheries ultimately led to the identification of aflatoxin B1 (AFBI) as a potential human hepatocarcinogen (26) (27) (28) (2) o-AAT HCC, CCC (6) DMAB HCC, cholangioma
MAMA Pancreatic ACC, AC
AFB, Hepatic Target organa  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV  LV,ST,SB,K  LV  LV,K  LV,ST,SB  LV  LV  LV  LV  ST  LV,ST,K,SB  ST,K,SB,LV  LV,ST,K  LV,ST,SB,K  LV,ST,K,SB  SB,LV,ST,K  LV,ST,K,SB  LV  LV  LV  LV  ST,LV  LV,ST,K  ST,LV,SB,K  LV,ST  ST,LV,SB  ST, LV  LV   LV  LV  LV  LV  LV   Reference  (28,31 (64) (Figure 2 ). Another type of mixed carcinoma contains just biliary and pancreatic components.
The second most abundant tumor type (25-30%) is the pure hepatocellular carcinoma ( Figure 3 ). These tumors are composed of broad tubules of basophilic hepatocytes, with many cells between adjacent sinusoids and frequent mitotic figures. Cholangiocellular carcinomas are rare, usually less than 1%, but consist of ducts or sheets of cells, have minimal stroma, and are invasive into surrounding liver tissue ( Figure 4 ). All these malignant tumor types are capable of distant metastasis or direct growth into surrounding visceral tissues, but we rarely see this occur within the 9-to 12-months time frame of most of our experiments. Metastases are rather common if the fish are held for 2 years or longer.
Several nonmalignant tumors are also observed. Hepatocellular adenomas tend to be small and noninvasive, with cells that are basophilic but occur within normalappearing hepatic tubules ( Figure 5 ). This is usually not an end-stage neoplasm but appears to progress to hepatocellular carcinoma. The prevalence varies depending on the time of termination, but in most cases, it is between 5 and 10%. Very rarely we observe an adenoma that is composed of eosinophilic hepatocytes, but the vast majority are basophilic. Very small foci of basophilic hepatocytes are interpreted to be the beginning stages of either hepatocellular adenomas or carcinomas and not a separate preneoplastic lesion. Cholangioma is an infrequent tumor type consisting of mostly normal-appearing bile ducts and abundant stroma that usually encapsulate the structure ( Figure 6 ). Usually 1 to 2% of the total incidence are cholangiomas. Mixed hepatocellular/cholangiocellular adenomas are tumors having the cellular features of adenomas and cholangiomas together in the same cellular mass ( Figure  7 ). These tumor types are seldom seen.
A final tumor type that has been observed only twice in over 30 years of histopathologic examinations of tens of thousands of liver sections is what we interpret to be a hepatoblastoma. These two tumors consist of deeply basophilic, highly undifferentiated cells with an extremely high rate of mitosis ( Figure 8 ). The cells palisade around vascular channels and outstrip the vascular supply to the rapidly expanding cellular mass. This leads to extensive necrosis that extends into veins and causes serious hemorrhaging ( Figure 9 ).
Kidney. The nephroblastoma is an almost exclusive chemically inducible neoplasm of trout kidneys. It consists of deeply basophilic, highly mitotic blastema cells; abortive, poorly differentiated glomerular structures; incompletely differentiated tubules; and abundant connective tissue stroma ( Figure 10 ). Six carcinogens, listed in Table 2 , have produced nephroblastomas, but the treatment of choice for producing a high incidence of these tumors is a static waterbath exposure of rainbow trout fry to a solution of 50 ppm MNNG for 30 min. This will result in about 50% of the fish having one or more large nephroblastomas 6 to 9 months later. These tumors grow rapidly, become very large, and kill the fish through destruction of normal kidney tissue and obstruction of urine flow. To our knowledge, the rainbow trout is the only animal model in which nephroblastoma can be routinely initiated in a high incidence by a chemical carcinogen (72) .
Stomach. All the stomach tumors that we have observed in rainbow trout have been benign papillary adenomas of the mucosal lining of the glandular stomach. Typically, they grow upward into the luminal space. Some tumors produced by dietary exposure to MNNG (56) also exhibited downward growth but never penetrated the basement membrane ( Figure 11 ).
Swim Bladder. As with the stomach tumors described above, the swim bladder adenomas are benign papillary overgrowths of epithelial cells that protrude into the lumen of the swim bladder. The unique feature of the cells of this lesion is the marked increase in size of the tumor cells compared with the normal mucosal cells. The columnar height of these cells is often several times greater than the normal cells ( Figure 12 ).
This brief review of the procedures involved in the initiation and identification of neoplasms in rainbow trout is intended to portray this model as a viable alternative for many aspects of cancer research. The fish are easy and economical to rear, and they respond to classical carcinogens in a predictable, dose-responsive manner.
Pathways of Procarcinogen Metabolism, DNA Adduction, and Repair
Cytochromes P450
As is the case in humans (73) (80) . The properties of LM4a were similar to the major isoform purified, LM4b (CYPlA 1). We do not yet know if LM4a corresponds to the protein encoded by the recently cloned trout CYP1A2 (84) . bLMC5 and P450Con were purified independently by two different laboratories, both of which have preliminary evidence that this trout P450 has many properties in common with mammalian CYP3A (85, 94, 95 (105) . In trout, the majority of AFBI 8,9-epoxygenation is catalyzed by CYP2K1 (89) . The covalent adduct produced is the same as in mammals, 8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1 (AFB1-N7-GUA) (106, 107) .
As is the case in mammals, trout CYPIA is active in the hydroxylation at the 10 position to produce AFMI (108) . The induction of CYPIA by compounds such as 0-naphthoflavone (BNF), indole-3-carbinol (W3C), and polychlorinated biphenyls (PCBs) was thought to be the mechanism by which these modulators acted as chemopreventors of AFBI-initiated hepatocarcinogenesis in trout (109, 110) .
However, recently our laboratory has determined that inhibition of CYP activity may be a more important mechanism of action than CYPlA induction, especially with I3C (111) (112) (113) (114) . In studies examining the time course and dose response of dietary I3C, trout responded only weakly and transiently to this compound as an CYPIA inducer, and the degree of reduction in covalent binding of AFB1 to DNA in vivo did not correlate to CYPIA induction (111, 112) . Similarly, BNF was found to significantly reduce AFB1 covalent binding to DNA at dietary doses too low for CYPIA induction (114) . In the course of these studies, we found that both BNF and various acid condensation products of I3C were potent inhibitors of a number of trout and mammalian CYPs, with inhibition contents well below the levels known to be attained in liver after administration of anticarcinogenic doses (112) (113) (114) (115) .
In addition to possessing a CYP (2K1) with high activity toward bioactivation of AFBI, the remarkable sensitivity of trout toward AFBI-initiated carcinogenesis can be explained by their lack of a constitutive or inducible glutathione S-transferase (GST) with appreciable activity toward AFB,-8,9-epoxide (116) . The high activity displayed by constitutive mouse Yc GST, compared to rat, is thought to be the major factor for the remarkable resistance of mice (98, (117) (118) (119) (120) (121) . The importance of this enhanced phase II reaction is confirmed by the observation that mice are actually more prolific at production of AFBI-8,9-epoxide than rats. Administration of 13C to rats induces a form of GST (Yc2) with high activity toward conjugation of the exo-AFB,-8,9-epoxide and presumably contributes to chemoprevention in this animal model (122) . Trout, however, appear refractory toward induction of this type of GST (116 (63, 136) , indicating that, as in mammals, metabolic activation occurs through N-deethylation. In rats, mice and humans, the major CYP catalzying 0-deethylation of DEN is CYP2E1, with some contribution from CYP2A6 (137) (138) (139) . Little information (140) is available on which trout CYPs may be responsible for N-dealkylation of DEN or other dialkylnitrosamines. To our knowledge, no ortholog of CYP2E1 has been identified in any fish. Pretreatment of trout with BNF enhances the hepatocarcinogenesis of DEN, suggesting a role for CYPIA (63) .
DNA Adduction and Repair
As discussed above, the major initial covalent AFB1-DNA adduct produced is the same in trout and mammals, trans-8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1, which is spontaneously converted to the more persistant ring-opened formaminopyrimidine. A (60, 151) . Thus in species as different as trout and mice, biochemical differences in procarcinogen metabolism and adduction can exist, which nonetheless lead to similar oncogenic pathways involving prevalent ras activation.
Treatment of trout with DEN produces dose-dependent increases in DNA adduction, primarily 7-ethylguanine and 06_ ethylguanine (63, 136) . The formation of the latter adduct correlates with tumor incidence and is consistent with the dominance of a G -A transition mutation in Ki-ras isolated from these tumors (53, 63) . This mutagenic specificity probably derives from ineffective alkyltransferase removal of 06-ethylguanine in these animals (53, 63) . Based on total tumorigenic dosage required, however, Shasta trout and F344 rats show comparable sensitivity to hepatocarcinogenesis by DEN (53).
Protooncogene Activation in Trout Tumors
An understanding of the molecular basis for cancer initiation, promotion, and progression is necessary to more readily relate cancer studies in fish to those in mammals including humans. Mutational inactivation of the p53 tumor suppressor gene (152) and activation of the ras protooncogene (153) (60) , and the Nnitroso compound DEN (53) . Table 4 summarizes current knowledge regarding Ki-ras mutational activation among the various tumor types elicited by these and additional carcinogens in trout. Overall, the data demonstrate that Ki-ras mutagenic activation can be a frequent event in the initiation of liver, stomach, and swim bladder neoplasms in the trout model. We have yet to establish full trout sequences for Nand Ha-ras homologues and to determine if mutations may also occur in these genes.
The Ki-ras mutational data have been accumulated by allele-specific hybridization, 3'-primer mismatch polymerase chain reaction analysis (MMA) and direct sequencing of polymerase chain reaction (PCR) products. Though sequencing provides a more direct identification of any mutant that may exist within the PCR (71-100%) of activated Ki-ras alleles. An interesting exception is dehydroepiandrosterone (DHEA), an endogenous steroid that is also hepatocarcinogenic in the rat but not previously known to be genotoxic. The mutant ras incidence of 32% (8/25) is low, but the 12(1)G-A mutation observed is not compatible with indirect damage such as 8- hydroxydeoxyguanosine. The precise origin of the observed ras mutations remains to be established. For DMBA, the incidence of Ki-ras mutations in liver tumors varied from 44% (7/16) to 100% (9/9) among the various experiments. The number of mutant alleles observed is too small at present to know if the DMBA mutational spectrum is protocol dependent. Among (Table 4) and rats (156) show frequent ras mutation, yet this has not been reported to occur in hepatocellular carcinoma from AFB1-exposed humans. Mutant Ha-ras alleles have, however, been reported in human cholangiocellular carcinoma (157) . We are attempting to establish if ras mutation in the trout may also be restricted to neoplasms having cholangiocellular involvement. An alternative hypothesis is that the-trout and rat laboratory models do not completely mimic AFBI -related human hepatocarcinogenesis, which may frequently involve tumor progression under the combined influence of chronic carcinogen intake and hepatitis infection.
Tumor Promotion and Inhibition in Trout
Use of the trout tumor model to study modulation of carcinogenesis has been reviewed elsewhere (158) (159) (160) . The historically low spontaneous liver tumor incidence (0.1%) is a significant advantage in the statistical design of multidose tumor inhibition and promotion experiments. In this overview, we will summarize some past results and also present some recent unpublished findings.
The majority of studies on anticarcinogenesis has focused on inhibition of AFB1-initiation of hepatocarcinogenesis ( (dose at 50% incidence). The IC50 (median-inhibiting concentration) was estimated at 1,400 ppm 13C. hA 9500-animal experiment similar to the one above was performed with four different dietary levels of chlorophyllin at six different doses of AFB1. Again, plots of % logit tumor response versus log AFB1 dose gave parallel lines increasingly displaced to the right with increasing doses of chlorophyllin. A 70 to 80% protection was achieved at dietary levels of 1,500 ppm chlorophyllin. cThis was a recently completed 9,600-animal experiment with multiple doses of both 13C and DMBA. 13C was able to completely block tumors in the swim bladder and inhibited tumor formation in the liver and stomach by 60 to 75%.
inhibitors. For (Table 6 ), yet to date, co-treatment with antioxidants has not provided any protection. Our laboratory is currently studying the mechanism of 13C dietary modulation of cancer using trout and murine models. If given before and during initiator exposure, I3C functions in trout as an anticarcinogen, but chronic postinitiation exposure enhances tumorigenesis. These opposing actions have similar potencies (EC50 [median effective concentration] = 1,000-1,500 ppm) in trout (42) . The mechanism of I3C inhibition in trout appears to be largely due to inhibition of CYP bioactivation by I3C acid condensation products rather than aryl hydrocarbon (Ah) receptor-dependent induction of CYPlA (111) (112) (113) .
We are currently investigating the role of the Ah receptor in tumor promotion. Previous studies have documented that a number of I3C acid condensation products have high affinity for the mammalian Ah receptor (167) . Inititial attempts to block trout Ah receptor-dependent promotion with a-naphthoflavone (ANF) were unsuccessful. In fact, ANF alone in trout was a promoter of hepatocarcinogenesis, and the combination of ANF and BNF was additive (Table 6 ). Further work has documented that ANF is an Ah receptor agonist in trout. We had hoped to use congenic mice to directly address the role of the Ah receptor in I3C promotion; however, preliminary studies indicated that I3C fails to promote hepatocarcinogenesis in mice (DEN) as it does in rats (AFB1) (DE Williams, unpublished observations).
Our laboratory has recently found DHEA to be a potent promoter in the trout model (Table 6) , and in fact it is a complete carcinogen (165) . DHEA has received much attention recently with respect to its chemopreventive properties in humans and animal models with respect to a number of diseases including atherosclerosis, diabetes, obesity, lupus, trauma injury, AIDS, and in aging (168) . Currently, a number of clincial trials are being conducted with DHEA, an agent that is also being marketed in health food stores. DHEA is hepatocarcinogenic in rats under protocols requiring high doses (.4,500 ppm) over long exposure periods (2 1 year). The carcinogenicity of DHEA in rodents is thought to be caused by its actions as a peroxisome proliferator (169) .
Environmental Health Perspectives * Vol 104, Supplement * Humans are relatively insensitive to peroxisome proliferators; therefore, the rodent findings are thought not applicable to human risk assessment (170) . Our findings with the trout model are the first to document the carcinogenicity of DHEA in the absence of peroxisome proliferation. Significant promotion in trout is observed in as little as 8 weeks of feeding (5 days per week) at levels that approximate doses previously used in some human clinical trials. The mechanism of DHEA promotion in trout may be hormonal. DHEA is a precursor for both estrogens (already known to promote hepatocarcinogenesis in trout) and androgens, and the plasma levels of both steroids increase markedly in trout fed DHEA. The estrogenic potency of DHEA in trout can be observed by following vitellogenin levels in plasma. The DHEA analog (171) developed by Arthur Schwartz (Temple University), 16a-fluoro-5-androsten-17-one (8354), was much weaker as a precursor for androgens and estrogens in trout, was not a complete carcinogen, and did not significantly promote AFB1 hepatocarcinogenesis at a dietary level (444 ppm) for which DHEA was very effective (165) and three different doses of AFB, demonstrated a linear relationship between % logit tumor incidence and log AFB1 with increasing doses of 13C displacing the line to the left. The calculated P50 (dose producing 50% promotion) for 13C promotion of AFB1 hepatocarcinogenesis was 1000 ppm. We are currently repeating this study with more AFB, and 13C doses to determine if a threshold exists for 13C promotion. bp-Estradiol also enhanced tumor multiplicity and tumor size. cDietary DHEA produced marked hypertrophy and cell proliferation in trout. In addition, we have evidence that DHEA may disrupt control of the cell cycle as evidenced by alterations of p53 and PCNA.
DHEA also dramatically enhances blood levels of vitellogenin in these sexually immature fish. dTrout were fed diets containing 1800 or 2500 ppm H202 alone, 5 or 10 ppm P-estradiol alone, or combinations of these two doses.
Both compounds promoted AFB, hepatocarcinogenesis. The combination diets were less that additive.°H202 also enhanced tumor multiplicity. The degree of enhancement of tumor incidence significantly correlated to oxidative damage to DNA, as evidenced by liver DNA levels of 8-hydroxy-2'-deoxyguanosine. fin liver, DHEA produced a dose-dependent enhancement of tumor incidence from 1% at 0 ppm to 99% at 888 ppm. Tumor multiplicity and size were also significantly increased in a dose-dependent manner. Kidney tumors were also significantly enhanced at 111 and 888 ppm DHEA. In contrast, DHEA significantly inhibited MNNG-initiated tumors of the stomach and swim bladder. instead assesses cancer risk through the embryonic and juvenile lifestages, which are not unimportant. Moreover, any chemical that is positive in a trout carcinogen bioassay should reasonably be considered a potential human carcinogen, barring mechanism information to the contrary.) A final limitation of the trout model is the continuing lack of knowledge in this species of fundamentals in the genetics and cell biology of cancer; owing to the relatively few investigators involved in its development, this is likely to remain a chronic problem.
Even with these limitations, there are many attributes of trout and other fish models that afford unique approaches in the study of cancer. Where mechanistically reasonable, the use of trout and other fish models can substantially reduce our dependence on small mammals for health research. Cost is a considerable advantage, especially for investigating statistically challenging issues that can be addressed only with large numbers of animals. Our molecular dosimetry studies using 8,000 to 10,000 animals to quantify the interrelationships among carcinogen dose, anticarcinogen dose, DNA adduct formation, and final tumor outcome exemplify this (35, 162) . Similarly, the low husbandry costs for fish permit tumor studies designed to define the shape of cancer dose-response curves down to 0.1% incidence. The design of any such experiment requires at least 31,000 animals to provide adequate statistical power, given the expectation of only 10 tumors among 10,000 animals at the targeted lowest dose. One such experiment is in progress testing DEN in the medaka model. DBP and DEN will be similarly tested in the next 2 years in the trout model, together with biochemical studies of metabolism, DNA adduction and repair, Ki-ras activation, target organ toxicity, and proliferation that aim to define mechanisms accompanying any departure from linearity. An advantage of trout inherent in this study is its historically zero background tumor rate in two of the target organs, which assures that all observed tumors in these organs can be ascribed to carcinogen treatment. In the third organ, liver, the historic background tumor rate of 0.1% will become important at the lowest carcinogen dose only. Even here, given the high incidence of activated Ki-ras in carcinogen-initiated tumors only, it may be possible to separate almost all carcinogenrelated and spontaneous tumors. The entire tumor study, including in-house pathology as well as the proposed mechanism studies, is to be carried out with trout for a total budget that is only 5 (46) , and we have generated entire tumor dose-response curves with 2,000 individuals, requiring less than 100 pg total of AFM1 and related aflatoxins (GS Bailey, unpublished data). We have determined that a measured dose of 0.5 ng AFB1 per trout embryo will induce 26% incidence of hepatic tumors 9 months after embryo injection; this is nine orders of magnitude lower than the dose of AFB1 required to elicit a similar response in monkeys. No other established cancer model offers this sensitivity.
Finally, the nonmammalian status of trout also has its inherent advantages in that a comparative approach in cancer research is no less useful than in other fields of biology. Thus the establishment of ras activation as a common oncogenic pathway in trout strongly supports a commonality in molecular mechanisms of cancer in lower and higher vertebrates. The fact that trout are more humanlike than rats in their resistance to the phenomenon of hepatic peroxisome proliferation makes them an attractive species in which to establish if peroxisome proliferators might pose carcinogenic risk by mechanisms other than peroxisome proliferation itself-as discussed above, we now know that some of these compounds are complete carcinogens and are possible genotoxins in trout. AFB1 hepatocarcinogenesis can be blocked in rats by co-treating animals with the antioxidant ethoxyquin (172) or the antischistosomal drug Oltipraz (173) , apparently through induction of GST Yc2 with high specificity for AFB1-8,9-oxide. (34) and later confirmed in rats (174) , that the candidate anticarcinogen indole-3-carbinol can behave as a potent tumor promoter under some exposure protocols has raised as yet unresolved safety concerns over its proposed use in human breast cancer chemoprevention.
In summary, it is evident that there are many experimental situations in which trout and other fish models are inadequately developed or inappropriate to address certain issues in cancer research. It is equally apparent that these species can serve as highly useful adjuncts to the traditional rodent models in the study of human environmental cancer risks and in some situations can provide wholly unique approaches.
